NATCO Pharma Past Earnings Performance
Past criteria checks 2/6
NATCO Pharma has been growing earnings at an average annual rate of 37.4%, while the Pharmaceuticals industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 21.3% per year. NATCO Pharma's return on equity is 18%, and it has net margins of 34.1%.
Key information
37.42%
Earnings growth rate
37.78%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.49% |
| Revenue growth rate | 21.33% |
| Return on equity | 17.97% |
| Net Margin | 34.13% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Narrative Update • May 03
NATCOPHARM: Future Diabetes And Oncology Launches Will Face Softer Expectations
Analysts have kept the fair value estimate for NATCO Pharma steady at ₹938.10 per share, reflecting unchanged assumptions around discount rate, revenue trends, profit margin and future P/E, and signalling no shift in their overall price target rationale. What's in the News NATCO received Central Drugs Standard Control Organisation approval to manufacture and market generic Semaglutide injection in India, with a launch planned in March 2026 targeting adults with insufficiently controlled type 2 diabetes (Key Developments).Narrative Update • Apr 18
NATCOPHARM: Future Diabetes Launch Will Face Softer Revenue Expectations
Analysts have revised their price target on NATCO Pharma from ₹982.64 to ₹938.10, citing updated assumptions that reflect softer revenue expectations, a higher projected profit margin and a lower future P/E multiple. What's in the News Launch of generic Semaglutide injection in India planned for March 2026, with multi dose vials priced at MRP of ₹1,290 per month for 2mg/1.5ml and 4mg/3ml, and ₹1,750 for 8mg/3ml, plus pen devices in April 2026 at MRPs of ₹4,000, ₹4,200 and ₹4,500 per month.
Narrative Update • Apr 04
NATCOPHARM: Diabetes Partnership And New Launches Will Support Future Upside
Analysts have trimmed their price target on NATCO Pharma to ₹1,391.29, reflecting slightly softer assumptions on revenue growth and profit margins, along with a modestly higher future P/E multiple. What's in the News NATCO received Central Drugs Standard Control Organisation approval to manufacture and market generic Semaglutide injection in India, with a launch planned in March 2026 for adults with insufficiently controlled type 2 diabetes (CDSCO approval).Narrative Update • Mar 21
NATCOPHARM: Diabetes Franchise Partnership And Demerger Plan Will Support Future Upside
Analysts have nudged their fair value estimate for NATCO Pharma slightly higher from ₹1,378.76 to ₹1,391.29, citing small adjustments to expected revenue contraction, profit margins and future P/E assumptions. What's in the News The board is scheduled to meet on March 24, 2026 to consider a Scheme of Arrangement to demerge the Agrochemicals Division into wholly owned subsidiary Natco Crop Health Sciences Limited, on a going concern basis (Board Meeting).Narrative Update • Mar 06
NATCOPHARM: Domestic Diabetes Franchise Partnership Will Support Future Upside
Analysts have made only a marginal tweak to their fair value estimate for NATCO Pharma, keeping the price target effectively steady at about ₹1,379 as they fine tune assumptions around revenue contraction, profit margins and future P/E expectations. What's in the News Eris Lifesciences announced a partnership with NATCO Pharma to commercialise semaglutide in India, combining Eris's diabetes franchise with NATCO's manufacturing and regulatory capabilities for complex formulations (Client Announcement).Narrative Update • Feb 20
NATCOPHARM: New Subsidiaries And Leadership Changes Will Support Future Upside
Analysts have trimmed their price target on NATCO Pharma slightly, from about ₹1,414.64 to ₹1,378.76. This reflects updated assumptions around revenue contraction, profit margins, and future P/E expectations.Analysis Article • Feb 17
NATCO Pharma Limited Just Missed Revenue By 8.4%: Here's What Analysts Think Will Happen Next
NATCO Pharma Limited ( NSE:NATCOPHARM ) just released its latest third-quarter report and things are not looking great...Analysis Article • Feb 15
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.50
The board of NATCO Pharma Limited ( NSE:NATCOPHARM ) has announced that it will pay a dividend on the 14th of March...Narrative Update • Feb 06
NATCOPHARM: Dividend Prospects And Stable Outlook Will Drive Future Upside
Analysts have kept their fair value estimate for NATCO Pharma steady at ₹1,414.64 per share, with a slightly lower discount rate and a marginally higher assumed future P/E multiple. This reflects fine tuning of their views on revenue declines and profit margins rather than a fundamental shift in the outlook.Narrative Update • Jan 22
NATCOPHARM: U.S. Immunosuppressant Launch And Dividend Potential Will Drive Upside
Narrative Update Analysts have nudged their fair value estimate for NATCO Pharma to ₹1,414.64 from ₹1,405.34, reflecting slightly softer revenue and profit margin assumptions, partially offset by a modestly higher future P/E multiple. What's in the News Board meeting scheduled for November 14, 2025, to review unaudited financial results for the quarter and half year ended September 30, 2025, and to consider a second interim dividend for the 2025-26 financial year (company filing).Analysis Article • Jan 13
Insufficient Growth At NATCO Pharma Limited (NSE:NATCOPHARM) Hampers Share Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 25x, you may consider NATCO...Narrative Update • Jan 08
NATCOPHARM: Legal Win On Risdiplam Will Support Bullish Upside Ahead
Analysts have nudged their fair value estimate for NATCO Pharma slightly higher to ₹1,405.34, citing updated assumptions that reflect a softer revenue outlook and profit margin expectations, together with a higher future P/E of 54.34x. What's in the News NATCO Pharma has scheduled a board meeting on November 14, 2025 to consider unaudited financial results for the quarter and half year ended September 30, 2025, and to review a possible second interim dividend for the 2025-26 financial year (company filing).Narrative Update • Dec 15
NATCOPHARM: Risdiplam Court Victory Will Drive Bullish Upside Ahead
Analysts have trimmed their price target for NATCO Pharma slightly to approximately ₹1,405 from about ₹1,415. This reflects marginally weaker expectations for revenue growth and profit margins, even as future valuation multiples edge higher.Analysis Article • Dec 13
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 22
Earnings Troubles May Signal Larger Issues for NATCO Pharma (NSE:NATCOPHARM) Shareholders
The subdued market reaction suggests that NATCO Pharma Limited's ( NSE:NATCOPHARM ) recent earnings didn't contain any...Analysis Article • Nov 17
NATCO Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, NATCO Pharma Limited ( NSE:NATCOPHARM ) came out with a strong set of quarterly numbers that could...Analysis Article • Sep 11
Investors Don't See Light At End Of NATCO Pharma Limited's (NSE:NATCOPHARM) Tunnel
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 28x, you may consider NATCO...Analysis Article • Jun 02
Analysts Just Slashed Their NATCO Pharma Limited (NSE:NATCOPHARM) EPS Numbers
Market forces rained on the parade of NATCO Pharma Limited ( NSE:NATCOPHARM ) shareholders today, when the analysts...Analysis Article • May 22
There's No Escaping NATCO Pharma Limited's (NSE:NATCOPHARM) Muted Earnings
With a price-to-earnings (or "P/E") ratio of 8.4x NATCO Pharma Limited ( NSE:NATCOPHARM ) may be sending very bullish...Analysis Article • Mar 24
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Mar 09
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Feb 19
Analysts Are More Bearish On NATCO Pharma Limited (NSE:NATCOPHARM) Than They Used To Be
The latest analyst coverage could presage a bad day for NATCO Pharma Limited ( NSE:NATCOPHARM ), with the analysts...Analysis Article • Feb 18
NATCO Pharma Limited (NSE:NATCOPHARM) Not Doing Enough For Some Investors As Its Shares Slump 30%
Unfortunately for some shareholders, the NATCO Pharma Limited ( NSE:NATCOPHARM ) share price has dived 30% in the last...Analysis Article • Feb 16
NATCO Pharma Limited (NSE:NATCOPHARM) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
It's shaping up to be a tough period for NATCO Pharma Limited ( NSE:NATCOPHARM ), which a week ago released some...
New Narrative • Feb 09
Future Revenue Will Decline As Competition Erodes Revlimid Pricing And R&D Costs Compress Margins
Uncertainty in pricing and revenue from Revlimid could impact net margins and limit R&D expenditure.Analysis Article • Dec 23
Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider NATCO...Analysis Article • Dec 08
Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Nov 18
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
NATCO Pharma Limited's ( NSE:NATCOPHARM ) investors are due to receive a payment of ₹1.50 per share on 13th of...Analysis Article • Nov 15
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
NATCO Pharma Limited ( NSE:NATCOPHARM ) defied analyst predictions to release its second-quarter results, which were...Analysis Article • Oct 13
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Aug 13
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
NATCO Pharma Limited ( NSE:NATCOPHARM ) shares have continued their recent momentum with a 26% gain in the last month...Analysis Article • Jul 15
If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Jun 30
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 14
NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
With a price-to-earnings (or "P/E") ratio of 15.2x NATCO Pharma Limited ( NSE:NATCOPHARM ) may be sending very bullish...Analysis Article • May 30
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
NATCO Pharma Limited ( NSE:NATCOPHARM ) defied analyst predictions to release its annual results, which were ahead of...Analysis Article • May 09
Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
Key Insights NATCO Pharma's estimated fair value is ₹1,212 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
NATCO Pharma Limited ( NSE:NATCOPHARM ) has announced that it will pay a dividend of ₹1.25 per share on the 4th of...Analysis Article • Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
NATCO Pharma Limited ( NSE:NATCOPHARM ) investors will be delighted, with the company turning in some strong numbers...Analysis Article • Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
NATCO Pharma Limited ( NSE:NATCOPHARM ) shares have continued their recent momentum with a 25% gain in the last month...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How NATCO Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 45,626 | 15,572 | 6,938 | 0 |
| 30 Sep 25 | 43,901 | 15,387 | 6,760 | 0 |
| 30 Jun 25 | 43,958 | 16,976 | 6,215 | 0 |
| 31 Mar 25 | 44,319 | 18,854 | 6,002 | 0 |
| 31 Dec 24 | 42,800 | 18,651 | 5,886 | 0 |
| 30 Sep 24 | 45,638 | 19,448 | 5,689 | 0 |
| 30 Jun 24 | 43,490 | 16,365 | 5,288 | 0 |
| 31 Mar 24 | 40,020 | 13,883 | 5,360 | 0 |
| 31 Dec 23 | 38,298 | 12,778 | 5,537 | 0 |
| 30 Sep 23 | 35,637 | 11,274 | 5,665 | 0 |
| 30 Jun 23 | 29,630 | 8,152 | 4,730 | 0 |
| 31 Mar 23 | 27,085 | 7,153 | 4,733 | 0 |
| 31 Dec 22 | 24,074 | 3,890 | 5,037 | 0 |
| 30 Sep 22 | 24,754 | 4,071 | 5,163 | 0 |
| 30 Jun 22 | 24,191 | 4,154 | 4,595 | 0 |
| 31 Mar 22 | 19,462 | 1,700 | 5,005 | 0 |
| 31 Dec 21 | 16,833 | 2,735 | 4,659 | 0 |
| 30 Sep 21 | 14,780 | 2,558 | 4,491 | 0 |
| 30 Jun 21 | 18,990 | 3,931 | 4,278 | 0 |
| 31 Mar 21 | 20,561 | 4,409 | 4,507 | 0 |
| 31 Dec 20 | 21,756 | 4,820 | 5,043 | 0 |
| 30 Sep 20 | 23,026 | 5,238 | 5,007 | 0 |
| 30 Jun 20 | 19,861 | 4,404 | 3,770 | 0 |
| 31 Mar 20 | 19,150 | 4,608 | 4,774 | 0 |
| 31 Dec 19 | 19,159 | 4,875 | 3,807 | 0 |
| 30 Sep 19 | 19,904 | 5,425 | 3,762 | 0 |
| 30 Jun 19 | 20,482 | 6,060 | 3,664 | 0 |
| 31 Mar 19 | 20,945 | 6,444 | 4,466 | 0 |
| 31 Dec 18 | 24,066 | 8,235 | 4,008 | 0 |
| 30 Sep 18 | 24,121 | 8,815 | 3,863 | 0 |
| 30 Jun 18 | 22,953 | 7,838 | 3,512 | 0 |
| 31 Mar 18 | 21,848 | 6,962 | 3,422 | 0 |
| 31 Dec 17 | 19,817 | 5,730 | 3,124 | 0 |
| 30 Sep 17 | 20,895 | 5,506 | 2,975 | 0 |
| 30 Jun 17 | 21,679 | 5,323 | 2,546 | 0 |
| 31 Mar 17 | 20,202 | 4,860 | 2,698 | 0 |
| 31 Dec 16 | 17,697 | 3,680 | 2,071 | 0 |
| 30 Sep 16 | 13,692 | 2,113 | 2,187 | 0 |
| 30 Jun 16 | 12,431 | 1,748 | 1,960 | 0 |
| 31 Mar 16 | 10,423 | 1,549 | 1,918 | 0 |
| 31 Dec 15 | 9,355 | 1,494 | 2,569 | 126 |
| 30 Sep 15 | 8,549 | 1,266 | 2,432 | 126 |
| 30 Jun 15 | 8,390 | 1,294 | 1,454 | 0 |
Quality Earnings: NATCOPHARM has high quality earnings.
Growing Profit Margin: NATCOPHARM's current net profit margins (34.1%) are lower than last year (43.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NATCOPHARM's earnings have grown significantly by 37.4% per year over the past 5 years.
Accelerating Growth: NATCOPHARM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NATCOPHARM had negative earnings growth (-16.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11%).
Return on Equity
High ROE: NATCOPHARM's Return on Equity (18%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 04:18 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NATCO Pharma Limited is covered by 31 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Pranav Chawla | Ambit Capital |
| Gaurav Tinani | Ambit Capital |